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Introduction: 
Chondrocalcinosis is the calcification of cartilage seen in 
many diseases (e.g. hypophosphatasia, Wilson disease, and 
hemochromatosis); when caused  by the  deposition of 
calcium pyrophosphate (CPP) dihydrate crystals the specific 
term CPPD is used. CPPD has a poorly understood 
pathophysiology, but a simple explanation is that CPPD is 
caused by an excess of extracellular pyrophosphate (PPi) 
bound to calcium that is deposited into the cartilage of 
joints. A better understanding of this disease’s mechanism 
could lead to targeted treatment. In cases of autosomal 
dominant CPPD, mutations in the gene coding for ANKH 
have been observed. ANKH is proposed to function as a 
transporter of PPi; however, recent reports demonstrate 
that ANKH may also perform other functions. The purpose 
of this literature review is to  evaluate our current 
understanding of ANKH function in an effort to propose 
future lines  of research  that could target ANKH in 
CPP-containing diseases.
Methods:
Review was done using PubMed. Google Scholar did show 
other papers that did not come up in the PubMed search, but 
those papers were referenced in reviews that did show in the 
PubMed search. 
• Search terms included ANKH (where “H” infers human) and 
ANK – the original abbreviation for the progressive 
ankylosis gene in a mouse model. Recovered publications 
that included the term ANK in referring to the ankyrin 
family of proteins, as well as ankh, referring to the Egyptian 
amulet, were excluded.
Results:
Between 2000 and 2019, a total of 58 publications have 
explored the genetics and function of ANKH/ANK. The 
yearly number distribution of papers is shown in Figure 
1A. The distribution of subject matter with respect to 
ANKH is shown in Figure 1B. 
Most notable reports:
• ANKH has been shown to interact with other 
proteins in the development of CPPD. 
• Several diseases with evidence of calcification 
derangement are not linked to defects in ANKH, 
including ankylosing spondylitis 
• ANKH may also regulate ATP transport, and its 
expression is sensitive to oxygen
  Most recently: ANKH appears to play a critical 
intracellular role in endosomal recycling (Ref 3).
Discussion: 
Mutation in the ANKH gene was first described in 2000 in 
a phenotype of progressive ankylosis in a 
naturally-occurring mouse model of abnormal 
mineralization. At that time, the ANKH transmembrane 
protein was proposed to act as a putative transporter for 
PPi. However, an exciting new role for ANKH was 
reported in 2016 with the discovery that loss of ANKH 
results in perinuclear accumulation of early endosomes 
and reduced transferrin receptor/transferrin (TfR/Tf) 
endocytosis (Ref 3). Hereditary hemochromatosis (HH) is 
caused by mutations in the HFE gene and is 
characterized by increased cellular uptake of iron via 
TfR/Tf endocytosis. Interestingly, >30% of patients with 
hemochromatosis suffer from CPPD. We hypothesize 
that iron overload may increase ANKH expression and 
potentiate increased generation of PPi. Experiments 
designed to explore ANKH expression and function in 
response to iron overload in HH patients  would provide 
evidence for the role of ANKH in PPi metabolism and 
subsequent CPP deposition in HH patients. Furthermore, 
such studies would provide a rationale for the 
pharmacologic targeting of ANKH expression and 
function in HH-CPPD sufferers. 
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Proposed role for  ANKH 
in the  endocytosis of Tf. 
Seifert et al (3) show that 
loss of ANKH results in 
reduced Tf endocytosis. 
We hypothesize that in 
HH patients, increased 
intracellular Fe increases 
ANKH expression, thus 
resulting in increased PPi 
generation and ensuing 
CPP deposition. 
TGN: trans-Golgi network
Fe: iron
